Sponsors
Translation 2024 is generously supported by our sponsors. You will be able to meet them at the conference. DPUK is grateful to all of them. We wish to be clear that our sponsors have provided support to Dementias Platform UK to cover the cost of running the conference, and that no sponsor has had any influence over the meeting's agenda or arrangements.
OUR SPONSORS FOR TRANSLATION 2025
 |
Alamar Biosciences is unlocking the future of neurological diagnostics with high-sensitivity and multiplex protein detection in biofluid samples. The NULISAseq™ CNS Disease Panel 120 provides multiplex analysis of biologically informed content with the highest-sensitivity and broadest dynamic range. Analysis of 120+ proteins supports protein biomarker discovery and validation studies and includes biomarkers such as GFAP, UCH-L1 and alpha-synuclein. Complementing this, the NULISAseq™ Inflammation Panel contains ~250 important markers enabling comprehensive analysis of immune and inflammatory diseases. The NULISA immunoassays run on the innovative ARGO™ HT System, delivering a fully automated workflow and comprehensive multiplex data analysis in <16 hours. |
 |
The Alzheimer’s Disease Data Initiative is a coalition of leading academic, advocacy, government, industry, and philanthropy organizations that recognizes the need for dementia researchers to find easier ways to share unpublished data, analytical tools, and scientific findings. These partners are working together to accelerate progress towards new diagnostics, treatments, and cures in Alzheimer’s disease and related dementias. Learn more about the Alzheimer’s Disease Data Initiative at www.alzheimersdata.org. |
 |
Alzheimer’s Research UK is the UK’s leading dementia research charity. We are working to revolutionise the way we treat, diagnose and prevent dementia. And then, we will find a way to cure it. To do this, we’re funding the most forward-thinking scientists. In 2024, we invested £25.7m across 26 institutions through our grant schemes. These grants span PhD scholarships to pilot projects to senior fellowships. They cover a range of disease types, including Alzheimer’s and Parkinson’s disease, Frontotemporal and Vascular dementia, and dementia with Lewy Bodies. To find out more, please visit our website. |
 |
To tackle the UK’s biggest killer, we need a Society of people who understand all aspects of dementia and the realities of a disease faced by 900,000 people in the UK. We’re pioneering the way for those experiencing dementia right now, and for all those yet to develop the disease in the future. As well as being a vital source of support to help people navigate the most frightening time of their lives, we’re a powerful force for change by funding groundbreaking research and campaigning to make dementia the priority it should be. |
 |
At Eisai, everything we do is dedicated to giving our first thought to patients, their families and caregivers through our human health care (hhc) philosophy. Our passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in therapeutic areas where there is a high unmet medical need, such as neurology. We take a holistic approach to support and care, focusing beyond symptom control to research and discover life-changing medicines for patients with chronic neurological disorders. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational workforce working across a global network of R&D facilities, manufacturing sites and committed marketing subsidiaries. We strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do. |
 |
|
 |
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit www.novonordisk.co.uk |
 |
RETURN TO TRANSLATION 2024 MAIN PAGE
